Literature DB >> 16400027

Neuronal or glial expression of human apolipoprotein e4 affects parenchymal and vascular amyloid pathology differentially in different brain regions of double- and triple-transgenic mice.

Tom Van Dooren1, David Muyllaert, Peter Borghgraef, Annelies Cresens, Herman Devijver, Ingrid Van der Auwera, Stefaan Wera, Ilse Dewachter, Fred Van Leuven.   

Abstract

Apolipoprotein E4 (ApoE4) is associated with Alzheimer's disease by unknown mechanisms. We generated six transgenic mice strains expressing human ApoE4 in combination with mutant amyloid precursor protein (APP) and mutant presenilin-1 (PS1) in single-, double-, or triple-transgenic combinations. Diffuse, but not dense, amyloid plaque-load in subiculum and cortex was increased by neuronal but not glial ApoE4 in old (15 months) double-transgenic mice, whereas both diffuse and dense plaques formed in thalamus in both genotypes. Neuronal and glial ApoE4 promoted cerebral amyloid angiopathy as extensively as mutant PS1 but with pronounced regional differences: cortical angiopathy was induced by neuronal ApoE4 while thalamic angiopathy was again independent of ApoE4 source. Angiopathy correlated more strongly with soluble Abeta40 and Abeta42 levels in cortex than in thalamus throughout the six genotypes. Neither neuronal nor glial ApoE4 affected APP proteolytic processing, as opposed to mutant PS1. Neuronal ApoE4 increased soluble amyloid levels more than glial ApoE4, but the Abeta42/40 ratios were similar, although significantly higher than in single APP transgenic mice. We conclude that although the cellular origin of ApoE4 differentially affects regional amyloid pathology, ApoE4 acts on the disposition of amyloid peptides downstream from their excision from APP but without induction of tauopathy.

Entities:  

Mesh:

Substances:

Year:  2006        PMID: 16400027      PMCID: PMC1592662          DOI: 10.2353/ajpath.2006.050752

Source DB:  PubMed          Journal:  Am J Pathol        ISSN: 0002-9440            Impact factor:   4.307


  68 in total

1.  Direct projections from the entorhinal area to the anteroventral and laterodorsal thalamic nuclei in the rat.

Authors:  H Shibata
Journal:  Neurosci Res       Date:  1996-09       Impact factor: 3.304

2.  Reducing cerebral microvascular amyloid-beta protein deposition diminishes regional neuroinflammation in vasculotropic mutant amyloid precursor protein transgenic mice.

Authors:  Jianting Miao; Michael P Vitek; Feng Xu; Mary Lou Previti; Judianne Davis; William E Van Nostrand
Journal:  J Neurosci       Date:  2005-07-06       Impact factor: 6.167

3.  Increased amyloid-beta42(43) in brains of mice expressing mutant presenilin 1.

Authors:  K Duff; C Eckman; C Zehr; X Yu; C M Prada; J Perez-tur; M Hutton; L Buee; Y Harigaya; D Yager; D Morgan; M N Gordon; L Holcomb; L Refolo; B Zenk; J Hardy; S Younkin
Journal:  Nature       Date:  1996-10-24       Impact factor: 49.962

4.  The low density lipoprotein receptor regulates the level of central nervous system human and murine apolipoprotein E but does not modify amyloid plaque pathology in PDAPP mice.

Authors:  John D Fryer; Ronald B Demattos; Lynn M McCormick; Mark A O'Dell; Michael L Spinner; Kelly R Bales; Steven M Paul; Patrick M Sullivan; Maia Parsadanian; Guojun Bu; David M Holtzman
Journal:  J Biol Chem       Date:  2005-05-11       Impact factor: 5.157

5.  beta-site amyloid precursor protein cleaving enzyme 1 increases amyloid deposition in brain parenchyma but reduces cerebrovascular amyloid angiopathy in aging BACE x APP[V717I] double-transgenic mice.

Authors:  Michael Willem; Ilse Dewachter; Neil Smyth; Tom Van Dooren; Peter Borghgraef; Christian Haass; Fred Van Leuven
Journal:  Am J Pathol       Date:  2004-11       Impact factor: 4.307

Review 6.  Amyloid beta-peptide: the inside story.

Authors:  Bertrand P Tseng; Masashi Kitazawa; Frank M LaFerla
Journal:  Curr Alzheimer Res       Date:  2004-11       Impact factor: 3.498

7.  Evidence that levels of presenilins (PS1 and PS2) are coordinately regulated by competition for limiting cellular factors.

Authors:  G Thinakaran; C L Harris; T Ratovitski; F Davenport; H H Slunt; D L Price; D R Borchelt; S S Sisodia
Journal:  J Biol Chem       Date:  1997-11-07       Impact factor: 5.157

8.  Familial Alzheimer's disease-linked presenilin 1 variants elevate Abeta1-42/1-40 ratio in vitro and in vivo.

Authors:  D R Borchelt; G Thinakaran; C B Eckman; M K Lee; F Davenport; T Ratovitsky; C M Prada; G Kim; S Seekins; D Yager; H H Slunt; R Wang; M Seeger; A I Levey; S E Gandy; N G Copeland; N A Jenkins; D L Price; S G Younkin; S S Sisodia
Journal:  Neuron       Date:  1996-11       Impact factor: 17.173

9.  Abeta is targeted to the vasculature in a mouse model of hereditary cerebral hemorrhage with amyloidosis.

Authors:  Martin C Herzig; David T Winkler; Patrick Burgermeister; Michelle Pfeifer; Esther Kohler; Stephen D Schmidt; Simone Danner; Dorothee Abramowski; Christine Stürchler-Pierrat; Kurt Bürki; Sjoerd G van Duinen; Marion L C Maat-Schieman; Matthias Staufenbiel; Paul M Mathews; Mathias Jucker
Journal:  Nat Neurosci       Date:  2004-08-15       Impact factor: 24.884

10.  Co-expression of nicastrin and presenilin rescues a loss of function mutant of APH-1.

Authors:  Dieter Edbauer; Christoph Kaether; Harald Steiner; Christian Haass
Journal:  J Biol Chem       Date:  2004-06-21       Impact factor: 5.157

View more
  19 in total

1.  Dendritic degeneration, neurovascular defects, and inflammation precede neuronal loss in a mouse model for tau-mediated neurodegeneration.

Authors:  Tomasz Jaworski; Benoit Lechat; David Demedts; Lies Gielis; Herman Devijver; Peter Borghgraef; Hans Duimel; Fons Verheyen; Sebastian Kügler; Fred Van Leuven
Journal:  Am J Pathol       Date:  2011-08-10       Impact factor: 4.307

2.  Amyloid precursor protein mediates monocyte adhesion in AD tissue and apoE(-)/(-) mice.

Authors:  Susan A Austin; Colin K Combs
Journal:  Neurobiol Aging       Date:  2008-12-05       Impact factor: 4.673

3.  Tg-SwDI transgenic mice exhibit novel alterations in AbetaPP processing, Abeta degradation, and resilient amyloid angiopathy.

Authors:  Gregory D Van Vickle; Chera L Esh; Ian D Daugs; Tyler A Kokjohn; Walter M Kalback; R Lyle Patton; Dean C Luehrs; Douglas G Walker; Lih-Fen Lue; Thomas G Beach; Judianne Davis; William E Van Nostrand; Eduardo M Castaño; Alex E Roher
Journal:  Am J Pathol       Date:  2008-07-03       Impact factor: 4.307

Review 4.  Cell-specific production, secretion, and function of apolipoprotein E.

Authors:  Maaike Kockx; Mathew Traini; Leonard Kritharides
Journal:  J Mol Med (Berl)       Date:  2018-03-07       Impact factor: 4.599

5.  Amyloid-β protein modulates the perivascular clearance of neuronal apolipoprotein E in mouse models of Alzheimer's disease.

Authors:  Harshvardhan Rolyan; Ann Caroline Feike; Ajeet Rijal Upadhaya; Andreas Waha; Tom Van Dooren; Christian Haass; Gerd Birkenmeier; Claus U Pietrzik; Fred Van Leuven; Dietmar Rudolf Thal
Journal:  J Neural Transm (Vienna)       Date:  2011-01-06       Impact factor: 3.575

6.  Innate immunity receptor CD36 promotes cerebral amyloid angiopathy.

Authors:  Laibaik Park; Joan Zhou; Ping Zhou; Rose Pistick; Sleiman El Jamal; Linda Younkin; Joseph Pierce; Andrea Arreguin; Josef Anrather; Steven G Younkin; George A Carlson; Bruce S McEwen; Costantino Iadecola
Journal:  Proc Natl Acad Sci U S A       Date:  2013-02-04       Impact factor: 11.205

Review 7.  Measuring target effect of proposed disease-modifying therapies in Alzheimer's disease.

Authors:  Randall J Bateman; William E Klunk
Journal:  Neurotherapeutics       Date:  2008-07       Impact factor: 7.620

Review 8.  Apolipoprotein E: structure and function in lipid metabolism, neurobiology, and Alzheimer's diseases.

Authors:  Yadong Huang; Robert W Mahley
Journal:  Neurobiol Dis       Date:  2014-08-27       Impact factor: 5.996

9.  Rodent A beta modulates the solubility and distribution of amyloid deposits in transgenic mice.

Authors:  Joanna L Jankowsky; Linda H Younkin; Victoria Gonzales; Daniel J Fadale; Hilda H Slunt; Henry A Lester; Steven G Younkin; David R Borchelt
Journal:  J Biol Chem       Date:  2007-06-07       Impact factor: 5.157

10.  Targeting the accomplice to thwart the culprit: a new target for the prevention of amyloid deposition.

Authors:  David R Borchelt
Journal:  J Clin Invest       Date:  2018-03-30       Impact factor: 14.808

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.